Gilead Sciences Inc. (GILD)

67.59
NASDAQ : Health Technology
Prev Close 66.37
Day Low/High 66.50 / 67.69
52 Wk Low/High 60.32 / 82.72
Avg Volume 7.60M
Exchange NASDAQ
Shares Outstanding 1.28B
Market Cap 85.09B
EPS 4.20
P/E Ratio 9.95
Div & Yield 2.52 (3.46%)

Latest News

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study Of Selonsertib In Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study Of Selonsertib In Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis...

An Interesting Week For Dividends

An Interesting Week For Dividends

It's behavioral finance at its finest, and makes for a fascinating debate.

Gilead Sciences Drops Following Earnings Miss

Gilead Sciences Drops Following Earnings Miss

The biotech company reports downside bottom-line results, though it beats on revenue.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

Gilead Sciences Announces 11 Percent Increase In First Quarter 2019 Dividend

Gilead Sciences Announces 11 Percent Increase In First Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 11% in the company's quarterly cash dividend, beginning in the first quarter of 2019.

Gilead Sciences Announces Fourth Quarter And Full Year 2018 Financial Results

Gilead Sciences Announces Fourth Quarter And Full Year 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2018.

Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell

Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell

Seagate, Hartford Financial and Gilead are set to report after the bell Monday.

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

And why maintaining a small position in defense stocks is important.

Google, Trump, General Motors, New England Patriots - 5 Things You Must Know

Google, Trump, General Motors, New England Patriots - 5 Things You Must Know

U.S. stock futures rise modestly as investors focus on stronger-than-expected jobs and manufacturing data from the United States last week; Google parent Alphabet reports earnings Monday after the closing bell; Donald Trump says there's a 'good chance' of a trade deal with China; the New England Patriots win their sixth Super Bowl title.

Agenus Closes $150 Million Immuno-Oncology Transaction With Gilead

Agenus Closes $150 Million Immuno-Oncology Transaction With Gilead

LEXINGTON, Mass., Jan.

Gilead Sciences To Release Fourth Quarter And Full Year 2018 Financial Results On Monday, February 4, 2019

Gilead Sciences To Release Fourth Quarter And Full Year 2018 Financial Results On Monday, February 4, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.

Japan's Ministry Of Health, Labour And Welfare Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir)

Japan's Ministry Of Health, Labour And Welfare Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir)

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection...

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Gilead Sciences To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7

Gilead Sciences To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that members of the executive management team will participate in a fireside chat at the 37 th Annual J.

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.

Gilead Sciences And Scholar Rock Announce Strategic Collaboration To Develop Novel Therapies For Fibrotic Diseases

Gilead Sciences And Scholar Rock Announce Strategic Collaboration To Develop Novel Therapies For Fibrotic Diseases

Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta...

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks finished the day higher on Monday as gains by tech stocks offset concerns over the fate of U.S.-China trade talks, and after the U.K. delayed a parliamentary vote on Brexit.

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

U.S. stock futures turn mixed as investors continue to express concerns over the fate of U.S.-China trade talks; Tesla's Elon Musk says, 'I do not respect the SEC'; Carlos Ghosn and Nissan are indicted in Japan for underreporting the former chairman's pay.

Gilead Sciences Names Daniel O'Day Chairman And Chief Executive Officer

Gilead Sciences Names Daniel O'Day Chairman And Chief Executive Officer

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O'Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019.

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Genotype 1-6

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) For Treatment Of Chronic Hepatitis C Virus Genotype 1-6

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection...

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a...

Kite Announces Updated Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite Announces Updated Data From ZUMA-3 Study Of KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company (Nasdaq: GILD), announced updated results from ZUMA-3, a single-arm Phase 1/2 study evaluating KTE-X19 (formerly KTE-C19), an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy, in adult patients with relapsed or...

Kite Announces Two-Year Data For Yescarta® (Axicabtagene Ciloleucel) In Patients With Refractory Large B-Cell Lymphoma

Kite Announces Two-Year Data For Yescarta® (Axicabtagene Ciloleucel) In Patients With Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.

TheStreet Quant Rating: C (Hold)